

BEIKE BIOTECHNOLOGY

Patient Case Study

Retinitis Pigmentosa

Male, 29 years old, February - March 2010

Background

Age: 29 years old

Sex: Male

Nationality: German

Date of Admission: February 23, 2010

Date of Discharge: March 25, 2010

Treatment Center: Qingdao Chengyang People's Hospital, China

Diagnosis on Admission: Retinitis Pigmentosa

Condition On Admission

Main presenting problem was night blindness and tunnel vision. Eye movement, light perception, and accommodation reflex were normal. Myopia noted on both eyes and routine eye test showed visual acuity of VOD 0.08 and VOS 0.08. All other routine tests and physical examinations showed no other abnormalities.

Treatment Schedule

Patient received 6 umbilical cord blood-derived stem cell (UCBSC) packets by intravenous (IV) injection, lumbar puncture (LP), and retrobulbar injection (RBI) as per schedule below (please note that the retrobulbar and last IV injection used the same stem cell packet):

Number	Date	Cell Type	Delivery Method	Side Effects
1	February 24, 2010	UCBSC	IV	none reported
2	March 1, 2010	UCBSC	LP	none reported
3	March 5, 2010	UCBSC	IV	none reported
4	March 10, 2010	UCBSC	IV	none reported
5	March 15, 2010	UCBSC	LP	none reported
6	March 22, 2010	UCBSC	RBI	none reported
7	March 22, 2010	UCBSC	IV	none reported

Condition On Discharge

After transplantation of stem cells the patient had no fevers, headaches, or other stem cell therapy related side effects. There was a measurable improvement in the patient's visual field and visual acuity after treatment and the family also felt that there were small improvements in their son's eyesight.

Related test reports: Visual Field Results (please note that the first results were measured 16 days into the treatment).

Eye	Visual Field Test	Mar. 10, 2010: Pre-Treatment	Mar.23. 2010: Post-treatment
Right Eye	MD (mean deficit)	-31.05	-30.95
	PSD (Pattern Standard Deviation)	6.86	5.66
Left Eye	MD (mean deficit)	-31.24	-29.66
	PSD (Pattern Standard Deviation)	5.31	6.51

Related test reports: Visual Acuity Results, measured by the patients own Ophthalmologist.

Eye	Pre-treatment	Post-treatment
Right Eye	0.08	0.10
Left Eye	0.08	0.10

Follow Up Information

Condition 3 months after treatment: Patient reported a moderate improvement in his quality of life. He noted that "night vision seems better and field of view seems better."

BEIKE BIOTECHNOLOGY CO., LTD.
9th Floor, Zhongke Building, 1 South Street
South Area, Shenzhen Hi-Tech Industrial Park
Shenzhen, China 518057

Tel: +86-755-8630-9277 Email: info@beikebiotech.com
Fax: +86-755-8630-9309 Web: www.beikebiotech.com